

ACUTE VIRAL HEPATITIS

- CLINICAL PRESENTATION.
- DIGNOSIS.
- EPIDEMIOLOGY OF VIRAL
HEPATITIS INFECTION A,B,C IN
KSA.
- MANAGEMENT.

INCIDENCE OF ACUTE HEPATITIS IN 5 HEPATOLOGY CLINICS IN KSA 2013

| Causes of Hepatitis | HAV | HBV | HCV | AIH | DILI |
|---------------------|-----|-----|-----|-----|------|
| KKUH | 7 | 3 | 1 | 11 | ? |
| NGH | 10 | 5 | 2 | 8 | 8 |
| AMC | 1 | 0 | 0 | 3 | 3 |
| KFH | 1 | 2 | 0 | 3 | ? |
| DAMMAM UN. | 2 | 1 | 0 | 1 | 5 |
| TOTAL | 21 | 11 | 4 | 26 | 16 |

Viral Hepatitis - Overview

Type of Hepatitis

| | A | B | C | D | E |
|-----------------------|---------------------------------------|--|--|---|----------------------------------|
| Source of virus | feces | blood/ blood-derived body fluids | blood/ blood-derived body fluids | blood/ blood-derived body fluids | feces |
| Route of transmission | fecal-oral | percutaneous permucosal | percutaneous permucosal | percutaneous permucosal | fecal-oral |
| Chronic infection | no | yes | yes | yes | no |
| Prevention | pre/post- exposure immunization | pre/post- exposure immunization | blood donor screening; risk behavior modification | pre/post- exposure immunization; risk behavior modification | ensure safe drinking water |



Diagnosis of hepatitis

- Patient history
- Physical examination
- Liver function tests
- Serologic tests

Symptoms and Signs

■ Pre-icteric phase

1. Anorexia
2. Fatigue
3. Nausea
4. Vomiting
5. Arthralgia
6. Myalgia
7. Headache
8. Photophobia
9. Pharyngitis
- 10.
- 11.

■ Icteric phase::

1. Enlarged liver
2. Tender upper quadrant
3. Discomfort
4. Splenomegaly (10-20%)
5. General adenopathy

■ Post-icteric phase

Lab Findings

1. LFT increase >5-10 times of normal
2. Markers of hepatitis B or C or A might be positive

DD:

1. Infectious Mononucleosis
2. Drug Induced Hepatitis
3. Chronic Hepatitis.
4. Alcohol Hepatitis
5. Cholecystitis, Cholelithiasis
- 6-Auto-immun hepatitis

MARKERS OF VIRAL HEPATITIS

- HBV MARKERS
- HCV MARKERS
- HAV MARKERS

Hepatitis B Markers

- anti-HBc → exposure (IgM = acute)
- HBsAg → infection (carrier)
- anti-HBs → immunity
- HBeAg → viral replication
- anti-HBe → seroconversion
- HBV-DNA → viral replication:

Hepatitis C Markers

- ANTI -HCV
- PCR-RNA HCV

Hepatitis A Markers

- HAV IgM
- HAV IgG

Hepatitis E Markers

- HEV IgM
- HEV IgG
- HEV RNA PCR

AUTOIMMUN HEPATITIS MARKERS

- ANF
- ANTI MITOCHONDRIAL AB
- ANTI SMOOTH MUSCLES ABS.

AUTOIMMUN HEPATITIS MARKERS

- ANA)
- ANTI MITOCHONDRIAL
- ANTI SMOOTH MUSCLES ABS


Complications

- 1.Chronic hepatitis → cirrhosis- HCC
- 2.Fulmnant hepatitis

FULMINANT HEPATITIS

- Definition: Hepatic Failure Within 8 Weeks Of Onset Of Illness.
- Manifestation: Encephalopathy and Prolonged PT
- Histopathology: Massive Hepatic Necrosis.

Natural History



* Seropositive for hepatitis B surface antigen and hepatitis B e antibody, seronegative for hepatitis B e antigen

† Seropositive for hepatitis B surface antigen and e antigen, seronegative for hepatitis B e antibody

Hepatitis B Virus Modes of Transmission

- Sexual
- Parenteral
- Perinatal



Concentration of Hepatitis B Virus in Various Body Fluids

| <u>High</u> | <u>Moderate</u> | <u>Low/Not Detectable</u> |
|----------------|-----------------|---------------------------|
| blood | semen | urine |
| serum | vaginal fluid | feces |
| wound exudates | saliva | sweat |
| | | tears |
| | | breastmilk |




Possible transmission route of HBV in KSA

- 1-Horisontal transmission (person to person) is the main transmission route
- 2-Perintal transmission (positive HBSAG mothers) especially if they are HBEAG positive
- 3- Heterosexual transmission
- 4-Illegal injection drug use
- 5- Contaminated equipment used for therapeutic injections and other health care related procedures
- 6- Folk medicine practice
- 7-Blood and blood products transfusion without prior screening


HBV INFECTION before and after vaccination program

OVERALL PREVALENCE OF HBsAg AMONG SAUDIS IN THE 80'S ACCORDING TO REGIONS




Al-Faleh. Annals of Saudi Medicine, 1988

PREVALENCE OF HBeAg AMONG HBsAg POSITIVE SAUDIS PREGNANT WOMEN (n = 20920)



FREQUENCY OF HBeAg AMONG HBsAg POSITIVE SAUDI CHILDREN (n=307)




PREVENTION STRATEGIES OF MINISTRY OF HEALTH IN KSA

Introducing HBV vaccine in EPI program; and

- Mandatory screening of blood donors and expatriates.
- Vaccination of risk groups.
- Health education especially among medical personnel.


History of HBV infection control in KSA



THE CURRENT EPI IN THE KINGDOM OF SAUDI ARABIA

- | | | | |
|----|--------------|-------------|-----------|
| 1. | At birth | BCG + | HB1 |
| 2. | At 6 weeks | DPT1 + OPV1 | Hb2 |
| 3. | At 3 months | DPT2 + OPV2 | |
| 4. | At 5 months | DPT3 + OPV3 | |
| 5. | At 5months | Measles | HB3 |
| 6. | At 12 months | MMR | |
| 7. | At 18 months | (DPT + OPV) | Booster 1 |
| 8. | At 4-6 years | (DPT + OPV) | Booster 2 |


COMPARISON OF PREVALENCE OF HBsAg AMONG SAUDI CHILDREN IN 1989 (n=4575) AND 1997 (n=5355) – ACCORDING TO AGE



Al Faleh, J Infect 1999

□ 1989 □ 1997

COMPARISON OF PREVALENCE OF HBsAg AMONG SAUDI CHILDREN IN 1989 (n=4575) AND 1997 (n=5355) – ACCORDING TO REGION




Al Faleh, J Infect 1999

Prevalence Of HBsAg Among Saudi Population Before & After Vaccination over 18 y



Long Term Seroconversion Rate Over 18 Years (Anti-HBS)



Age
N


1-2yr
637

1-12yr
3666


16-18yr
1365

* Al Faleh et al Annals of Saudi med 1993
** Al Faleh et al Journal of infection 1999
*** AlFaleh et al journal of infection2008


Long-Term protection of HB- vaccine over 18 years (anti-HBS>10IU/L)(n=1355)



CHANGING PATTERNS OF HBsAg POSITIVITY AMONG BLOOD DONORS IN MOH,CENTRAL BLOOD BANK 1994-2005



PREVALENCE OF HBsAg POSITIVITY AMONG BLOOD DONORS IN KKUH FROM 1987 TO 2008




PRI-MARITAL SCREENING برنامج الزواج الصحي

التهاب الكبد ب وج 1435-1429 هـ

HBV,HCV INFECTION FROM 2009-2014


| الكبد ب HBV | الكبد ج HCV | HIV | عدد المتقدمين NR.OF SCREENS |
|----------------|----------------|-------|-----------------------------------|
| 24103 | 5388 | 512 | 2.131.018 |
| 1% | 0.3% | %0.02 | |

عدد حالات التهاب الكبد ب وج 1429-1435هـ
(2009-2014)NR.OF POSITIVE HBV&HCV CASES
HCV=RED



Copyrighted Material
NEW YORK TIMES BESTSELLER

WHY HELPING OTHERS
DRIVES OUR SUCCESS



GIVE

and

TAKE

ADAM GRANT

"AS BRILLIANT AS IT IS WISE, THIS IS NOT JUST
A BOOK—IT'S A NEW AND SHINING WORLDVIEW."
—SUSAN CAIN, AUTHOR OF *QUIET*

Copyrighted Material



HCV INFECTION

Transmission of HCV

- **Percutaneous**
 - Injecting drug use
 - Clotting factors before viral inactivation
 - Transfusion, transplant from infected donor
 - Therapeutic (contaminated equipment, unsafe injection practices)
 - Occupational (needlestick)
- **Per mucosal**
 - Perinatal
 - Sexual




Nosocomial Transmission of HCV

- Recognized primarily in context of outbreaks
- Contaminated equipment
 - hemodialysis*
 - endoscopy
- Unsafe injection practices
 - plasmapheresis,* phlebotomy
 - multiple dose medication vials
 - therapeutic injections

* Reported in U.S.



Natural history



Marcellin, J Hepat 1999

Overall prevalence rate of HCV infection in KSA among children and adolescent during the last 18 yrs.

| 1989 | | 1997 | | 2008 | |
|--|----------------|---|----------------|--|---------------|
| No. of children | Positive (%) | No. of children | Positive (%) | No. of students | Positive (%) |
| 4496 | 39* (0.87%) | 5350 | 2** (0.04%) | 1357 | (5)3 0.22% |
| Diagnostic test only by 1 st -generation EIA kit. | | Diagnostic test by 3 rd -generation EIA kit and confirmatory test by RIBA kit. | | Diagnostic test by PCR for anti- HCV Positive cases. | |

* ALFaleh et al. Hepatology 1991

** ALFaleh Ann Saudi Med. 2003

Prevention Of HCV Transmission


- Avoiding shared use of Razors or brushes and any item that pierces the skin.
- Strict adherence of the universal precautions in health facilities.
- Educating and training of HCW's to the proper use of standard precautions
- Folk medicine?!

Copyrighted Material

#1 NEW YORK TIMES BESTSELLER

"An insightful, wonderfully new take on the world from one of my favorite thinkers." —MALCOLM GLADWELL

Originals



HOW
NON-CONFORMISTS
MOVE THE WORLD

Adam Grant

author of *Give and Take*


Foreword by SHERYL SANDBERG

Copyrighted Material



HAV INFECTION

Geographic Distribution of HAV Infection



HEPATITIS A VIRUS TRANSMISSION


- Close personal contact
(e.g., household contact, sex contact, child day-care centers)
- Contaminated food, water
(e.g., infected food handlers)
- Blood exposure (rare)
(e.g., injection drug use, rarely by transfusion)



Modes of HAV transmission


- Faeco-oral route (95%)
 - ==> person-to-person contact
 - ==> contaminated food or water
 - ==> salads and fruits washed in contaminated water
 - ==> contaminated shellfish
- Infected plasma (<5%)
- Sexual route (<5%)

COMPARISON OF PREVALENCE OF ANTI-HAV AMONG SAUDI CHILDREN IN 1989 (n=4375) AND 1997 (n=5255) – ACCORDING TO AGE




Al-Faleh et al. Saudi Med. J, 1999

COMPARISON OF PREVALENCE OF ANTI-HAV AMONG SAUDI CHILDREN IN 1989 (n=4375) AND 1997 (n=5255) – ACCORDING TO REGION



Changing pattern of Hepatitis A prevalence within the Saudi population over 18 yrs



| | | | |
|--------|----------|----------|-----------|
| Age | 1-10 YRS | 1-12 yrs | 16-18 yrs |
| Region | 13 | 13 | 3 |

*AlRashed R. Ann SM 1997

** AlFaleh et al SMJ 1999

*** AlFaleh et al WJG 2008

PREVENTING HEPATITIS A

- Hygiene (e.g., hand washing)
- Sanitation (e.g., clean water sources)
- Hepatitis A vaccine (pre-exposure)
- Immune globulin (pre- and post-exposure)

HEPATITIS A VACCINES

Recommended Dosages of Hepatitis A Vaccines

| <u>Schedule</u> <u>Vaccine</u> | <u>Age</u> <u>(yrs)</u> | <u>Dose</u> | <u>Volume</u> <u>(mL)</u> | <u>2-Dose</u> <u>(mos)</u> |
|-----------------------------------|----------------------------|--------------|------------------------------|-------------------------------|
| HAVRIX ®# | 1-18 | 720 (EL.U.*) | 0.5 | 0, 6-12 |
| | >18 | 1,440 | 1.0 | 0, 6-12 |
| VAQTA ®# | 1-18 | 25 (U**) | 0.5 | 0, 6-18 |
| | >18 | 50 | 1.0 | 0, 6-18 |

* EL.U. – Enzyme-linked immunosorbent assay (ELISA) units

** Units

has 2-phenoxyethanol as a preservative

has no preservative



NEW YORK TIMES BESTSELLER

HOW WILL
YOU MEASURE
YOUR LIFE?

CLAYTON M.
CHRISTENSEN

JAMES ALLWORTH
& KAREN DILLON

**THANK
YOU**